SCHEMBL29665207

SCHEMBL29665207

Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OC2CCN(C3CCC3)CC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 20/20 1.00
KCNH2 Q12809 5/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL119942 1.00 HRH3 (1.00) HRH3KCNH2
SCHEMBL4465874 0.98 HRH3 (0.96) HRH3KCNH2
SCHEMBL3265123 0.94 HRH3 (0.89) HRH3KCNH2
Hydrochloric Acid SCHEMBL4468307 0.90 HRH3 (0.81) HRH3KCNH2
SCHEMBL502064 0.88 HRH3 (1.00) HRH3KCNH2
SCHEMBL502383 0.88 HRH3 (1.00) HRH3KCNH2
SCHEMBL4481243 0.88 HRH3 (0.78) HRH3KCNH2
SCHEMBL4479379 0.86 HRH3 (1.00) HRH3KCNH2
SCHEMBL4467608 0.86 HRH3 (0.96) HRH3KCNH2
SCHEMBL502320 0.85 HRH3 (1.00) HRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4673146-A2 METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS Biohaven Therapeutics Ltd. (VG) 2026-01-07 EP claimed
WO-2024182465-A2 METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS ALCO THERAPEUTICS, LLC (US) 2024-09-06 WO claimed
EP-4251148-A1 HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER Richter Gedeon Nyrt. (HU) 2023-10-04 EP claimed
WO-2022113008-A1 HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER RICHTER GEDEON NYRT. (HU) 2022-06-02 WO claimed
EP-4673146-A2 METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS Biohaven Therapeutics Ltd. (VG) 2026-01-07 EP disclosed
WO-2024182465-A2 METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS ALCO THERAPEUTICS, LLC (US) 2024-09-06 WO disclosed
EP-4251148-A1 HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER Richter Gedeon Nyrt. (HU) 2023-10-04 EP disclosed
WO-2022113008-A1 HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER RICHTER GEDEON NYRT. (HU) 2022-06-02 WO disclosed